The Ohio State University
Columbus, Ohio, 43210, United States
NCT Number: NCT04063397
The investigators plan to enroll women with PE prospectively to evaluate incremental cardiovascular risk in those who have PE with severe features. This study includes detailed echocardiographic evaluation at several time points. With the current proposal, the investigators aim to collect blood to evaluate several biomarkers to determine if there is a correlation with short and medium-term cardiovascular risk. This opens the door to earlier detection, treatment and improved cardiovascular outcomes.
Looking for future studies?
Notify Me18 year and older
Female
Observational
Columbus, Ohio, 43210, United States
Preeclampsia (PE) is a multi-system progressive disorder affecting up to 8% of pregnancies. Epidemiologic studies have shown a significant association between PE and future cardiovascular disease (CVD) in women. Despite recognition of this relationship, there are no good markers to help determine which women are at highest risk, in particular as this relates to long-term cardiovascular risk, the number one cause of mortality in U.S. born women. As such, the study of PE and cardiovascular outcomes, in particular to identify early markers for the development of late CVD, provide insight into critical opportunities for early treatment and modification of disease trajectory in women.
The investigators plan to enroll women with PE prospectively to evaluate incremental cardiovascular risk in those who have PE with severe features. This study includes detailed echocardiographic evaluation at several time points. With the current proposal, the investigators aim to collect blood to evaluate several biomarkers to determine if there is a correlation with short and medium-term cardiovascular risk. This opens the door to earlier detection, treatment and improved cardiovascular outcomes.
The investigators hypothesize that preeclampsia with severe features confers a much higher risk of cardiovascular impairment compared to milder form of preeclampsia and healthy controls. If the hypothesis proves correct, these findings may change clinical practice by warranting routine echocardiogram for these patients for early recognition, intervention and treatment of cardiac dysfunction.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Serial echocardiograms will be done on all patients pre-delivery, and at 3-6 months
Serial blood draws at same time points as echocardiograms for biomarker levels
Time frame: From delivery up to 3-6 months postpartum
The following parameters will be measured to assess cardiac dysfunction:
Ohio State University
Other
Acronym: ECHO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07167862
Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases
Orange, California, United States
View Trial DetailsNCT05504811
Brain Diseases, Central Nervous System Diseases
Downey, California, United States
View Trial DetailsNCT03568461
Disease Attributes, Follicular Lymphoma
Duarte, California, United States
View Trial DetailsNCT05653271
B-cell Lymphoma, Burkitt Lymphoma
Orlando, Florida, United States
View Trial Details